studied, the mean percent total body weight loss was 10 percent (95 percent Confdence Interval, CI 7.3–12.7) and the mean waist circumference was reduced by 8.4cm (95 percent CI 5.7-11.8) at 4 months. Improvements were also seen in metabolic parameters (HbA1c, Low density lipoprotein, triglycerides and blood pressure). All aspects of quality of life measured by the Impact of Weight on Quality of Life (IWQoL) questionnaire demonstrated signifcant improvements. About safety, there were no serious adverse events or serious adverse device efects, however 64 percent of patients had vomiting, 54 percent experienced nausea, 25 percent had abdominal pain and 2 patients were excluded because of symptoms. CONCLUSIONS: The ELIPSETM gastric balloon for weight loss seems to be an efective therapy with an acceptable safety profle. However it would be necessary to continue further studies to confrm these results, including comparative studies with current treatments. ................................................................................... PP013 Pain Management And Substance Abuse In Sickle Cell Disease Patients AUTHORS: Mariana Santos, Diego Travi, Camila Ribeiro, Thiago Pianca, Indara Saccilotto, Lúcia Silla, Paulo Picon (paulopicon@gmail.com) INTRODUCTION: Drug abuse is a social and public health problem because of its negative consequences of emotional and physical development in individuals. There are few studies evaluating substance abuse by individuals with sickle cell disease (SCD). These patients have severe and recurrent pain crises (1), frequently needing opioids to control it (2). The compromised quality of life can predispose this population to the occurrence of non-psychotic disorders such as depression, making them vulnerable to substance abuse (3). METHODS: We evaluated the consumption of alcohol and drugs in a cohort followed at the Sickle Cell Disease Reference Center (CRAF), at Hospital de Clínicas de Porto Alegre, estimating the percentage of patients in treatment of SCD who abuse alcohol and drugs, mainly opioids. A cross-sectional study was of a convenience sample of 139 patients with SCD treated at CRAF. The pattern of substance use was evaluated using the Brazilian version of Alcohol, Smoking and Substance Involvement Screening Test (ASSIST). The exposure to opioids was measured by their use and prescription in the 24 months before the interview. The Self-Reporting Questionnaire (SRQ-20) was used to estimate the occurrence of non-psychotic disorders in this population. Descriptive analyses were performed using absolute and relative frequencies. The association between the variables was verifed using the chi-square test or Fisher’s exact test. RESULTS: The prevalence of abusive use was 1.5 percent for alcohol and 3.0 percent for tobacco, with no abusive use of any other substance including opioids was identifed. Of note was the pattern for substance use that was not infuenced by exposure to substances or the presence of non-psychotic disorders. CONCLUSIONS: Our data shows that use of opioid analgesics for the management of SCD painful crises is safe and does not induce substance abuse. Regular follow-up of these patients is recommended. The results of this study might be useful in other countries. REFERENCES: 1. Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease. Rates and risk factors. N Engl J Med. 1991;325(1):11-6. PubMed PMID: 1710777. Epub 1991/07/04. eng. 2. Smith WR, Dahman BA, Levenson JL, et al. Daily home opioid use in adults with sickle cell disease: The PiSCES project. J Opioid Manag. 2015;11(3):243-53. ................................................................................................................................................................................... POSTER PRESENTATIONS 73 https://doi.org/10.1017/S0266462317002057 Downloaded from https://www.cambridge.org/core. IP address: 207.241.231.82, on 25 Jul 2018 at 20:14:21, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms.